Selective cyclooxygenase 2 inhibitors and cardiovascular events
- 28 June 2005
- journal article
- review article
- Published by Wiley in Arthritis & Rheumatism
- Vol. 52 (7) , 1968-1978
- https://doi.org/10.1002/art.21132
Abstract
No abstract availableKeywords
This publication has 42 references indexed in Scilit:
- Cardiovascular Events Associated with Rofecoxib in a Colorectal Adenoma Chemoprevention TrialNew England Journal of Medicine, 2005
- Cardiovascular Risk Associated with Celecoxib in a Clinical Trial for Colorectal Adenoma PreventionNew England Journal of Medicine, 2005
- Complications of the COX-2 Inhibitors Parecoxib and Valdecoxib after Cardiac SurgeryNew England Journal of Medicine, 2005
- Framingham risk score and prediction of lifetime risk for coronary heart diseaseThe American Journal of Cardiology, 2004
- COX-2 and beyond: approaches to prostaglandin inhibition in human diseaseNature Reviews Drug Discovery, 2003
- Selective COX-2 inhibition and cardiovascular effects: a review of the rofecoxib development programAmerican Heart Journal, 2003
- Short- and Long-Term COX-2 Inhibition Reverses Endothelial Dysfunction in Patients With HypertensionHypertension, 2003
- Influence of Age and Cytochrome P450 2C9 Genotype on the Steady-State Disposition of Diclofenac and CelecoxibClinical Pharmacokinetics, 2003
- Gastrointestinal Toxicity With Celecoxib vs Nonsteroidal Anti-inflammatory Drugs for Osteoarthritis and Rheumatoid ArthritisJAMA, 2000
- Effects of Nonsteroidal Antiinflammatory Drugs on Platelet Function and Systemic HemostasisThe Journal of Clinical Pharmacology, 1995